Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Umezawa Hamao is active.

Publication


Featured researches published by Umezawa Hamao.


Biochemical Pharmacology | 1970

Inhibition of dopamine β-hydroxylase by fusaric acid (5-butylpicolinic acid) in vitro and in vivo

Nagatsu Toshiharu; Hidaka Hiroyoshi; Kuzuya Hiroshi; Takeya Kazumi; Umezawa Hamao; Takeuchi Tomio; Suda Hiroyuki

Abstract Fusaric acid (5-butylpicolinic acid) was found to be a potent inhibitor of dopamine β-hydroxylase in vitro and in vivo . Fusaric acid inhibited the enzyme by 50 per cent at a concentration of 3 × 10 −8 M. Kinetic studies with purified dopamine β-hydroxylase showed that the inhibition by fusaric acid was of the uncompetitive type with the substrate and of the mixed type with a cofactor, ascorbic acid. Fusaric acid lowered endogenous levels of norepinephrine and epinephrine in brain, heart, spleen and adrenal glands. Maximum depletion of norepinephrine and epinephrine was observed between 3 and 6 hr after the administration of fusaric acid. Since dopamine β-hydroxylase activity in adrenal medulla was found to be inhibited in vivo after the administration of fusaric acid, the decrease in the catecholamine levels is attributed to the inhibition of norepinephrine synthesis at the dopamine β-hydroxylase stage.


Biochimica et Biophysica Acta | 1983

Inhibition of brain prostaglandin d synthetase and prostaglandin D2 dehydrogenase by some saturated and unsaturated fatty acids

Osama Hiroyoshi; Narumiya Shuh; Hayaishi Osamu; Iinuma Hironobu; Takeuchi Tomio; Umezawa Hamao

The activities of rat brain prostaglandin D synthetase and swine brain prostaglandin D2 dehydrogenase were inhibited by some saturated and unsaturated fatty acids. Myristic acid was most potent among saturated straight-chain fatty acids so far tested. The IC50 values of this acid were 80 microM for prostaglandin D synthetase and 7 microM for prostaglandin D2 dehydrogenase, respectively. Little inhibition was found with methyl myristate and myristyl alcohol. The IC50 values of these derivatives were more than 200 microM for both enzymes, suggesting that the free carboxyl group was essential for the inhibition. The effects of cis double bond structure of fatty acids on the inhibition potency were examined by the use of the carbon 18 and 20 fatty acids. The inhibition potencies for both enzymes increased with the number of cis double bonds; the IC50 values of stearic, oleic, linoleic and linolenic acid were, respectively, more than 200, 60, 30 and 30 microM for prostaglandin D synthetase, and 20, 10, 8.5 and 7 microM for prostaglandin D2 dehydrogenase. Arachidonic acid also inhibited the activities of both enzymes with respective IC50 values of 40 microM for prostaglandin D synthetase and 3.9 microM for prostaglandin D2 dehydrogenase, while arachidic acid showed little inhibition. The kinetic studies with myristic acid and arachidonic acid demonstrated that the inhibition by these fatty acids was competitive and reversible for both enzymes. Myristic acid and other fatty acids also inhibited the activities of several enzymes in prostaglandin metabolism, although to a lesser extent. The IC50 values of myristic acid for prostaglandin E isomerase, thromboxane synthetase and NAD-linked prostaglandin dehydrogenase (type I) were 200, 700 and 100 microM, respectively. However, this fatty acid showed little inhibition on fatty acid cyclooxygenase (20% at 800 microM), glutathione-requiring prostaglandin D synthetase from rat spleen (20% at 800 microM), and NADP-linked prostaglandin dehydrogenase (type II) (no inhibition at 200 microM).


Archive | 1982

Tylosin derivatives, their preparation and pharmaceutical compositions containing them

Umezawa Hamao; Umezawa Sumio; Tsuchiya Tsutomu; Takeuchi Tomio; Tanaka Akihiro; Iwamoto Hidenori; Sakamoto Shuichi


Archive | 1977

1-N-((S)-' -HYDROXY-'7 -AMINOACYL)UMEZAWA; HAMAO<UMEZAWA; SUMIO<MAEDA; KENJI<TSUCHIYA; OSAMU<KONDO; SHINICHI<FUKATSU; SHUNZO

Umezawa Hamao; Umezawa Sumio; Maeda Kenji; Tsuchiya Osamu; Kondo Shinichi; Fukatsu Shunzo


Archive | 1982

DERIVES DE L-ARGININAL ET PROCEDE DE PREPARATION

Umezawa Hamao; Takeuchi Tomio; Aoyagi Takaaki; Ishii Shinichi; Saino Tetsushi; Someno Tetsuya


Archive | 1979

Intermediate and its preparation

Saino Tetsuyuki; Nishizawa Rinzou; Seya Kenji; Katou Kunimoto; Takita Tomohisa; Umezawa Hamao


Archive | 1978

1-N-{8 (S)-{60 -hydroxy-{107 -aminoacyl{9 {0 derivatives of 3{40 ,4{40 -dideoxykanamycin B and 3{40 -deoxykanamycin B antibiotics

Umezawa Hamao; Umezawa Sumio; Maeda Kenji; Tsuchiya Osamu; Kondo Shinichi; Fukatsu Shunzo


Archive | 1974

Method for treating parkinsonism

Nagatsu Toshiharu; Umezawa Hamao


Archive | 1972

Process for the synthesis of leupeptins and their analogues

Aoyagi Takaaki; Kondo Shinichi; Maeda Kenji; Takeuchi Tomio; Umezawa Hamao


Archive | 1979

Process for the synthesis of 3{40 ,4{40 -dideoxykanamycin B and products

Tsuchiya Tsutomu; Umezawa Hamao; Umezawa Sumio

Collaboration


Dive into the Umezawa Hamao's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge